PARP1

Global HR+/HER2-VE Breast Cancer Pipeline Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021
Pharmaceutical, Health, Oncology, Phase II, News, Clinical trial, BeiGene, II, Breast cancer, Therapy, III, PARP inhibitor, Acquisition, PARP2, Breast, PARP1, Cancer, Discovery, Medical imaging, Pharmaceutical industry

The "HR+/HER2-VE Breast Cancer - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HR+/HER2-VE Breast Cancer - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This HR+/HER2-VE Breast Cancer - Pipeline Insight, 2021 provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HR+/HER2-VE Breast Cancer pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence HR+/HER2-VE Breast Cancer R&D.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HR+/HER2-VE Breast Cancer drugs.

Global Gastric Cancer Pipeline Landscape Report 2021 - Comprehensive Insights About 100+ Companies and 100+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021
Pharmaceutical, Health, Oncology, News, Clinical trial, Mergers and acquisitions, II, Therapy, III, NMPA, Marketing, PARP inhibitor, Acquisition, PARP2, PD-1, PARP1, Enzyme, Discovery, Dietary supplement, Pharmaceutical industry, Vaccine

This Gastric Cancer - Pipeline Insight, 2021 provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Gastric Cancer pipeline landscape.

Key Points: 
  • This Gastric Cancer - Pipeline Insight, 2021 provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Gastric Cancer pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Gastric Cancer R&D.
  • This segment of the Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Cancer drugs.

Onxeo Receives Notice of Allowance for a New Patent Broadening the Protection of AsiDNA™ in combination with a PARP Inhibitor in the United States

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Biology, DNA repair, Cellular processes, Senescence, PARP inhibitor, Programmed cell death, Homologous recombination, PARP1, Poly (ADP-ribose) polymerase

This new patent completes, in a key territory, the already robust patent family protecting AsiDNA in combination with PARP inhibitors.

Key Points: 
  • This new patent completes, in a key territory, the already robust patent family protecting AsiDNA in combination with PARP inhibitors.
  • The DNA repair pathways, BRCA-dependent homologous recombination pathway and PARP pathway, are complementary and essential for tumor cell survival and proliferation.
  • If one pathway is deficient (homologous recombination by BRCA mutation) and the other is blocked by a PARP inhibitor, the tumor cell dies.
  • "This patent represents a further recognition in the strategic US market of the very original properties of AsiDNA.

Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors

Retrieved on: 
Thursday, October 22, 2020
Branches of biology, Biology, Cellular processes, PARP inhibitor, Homologous recombination, DNA repair, SiDNA, MRN complex, PARP1

It completes the already robust set of patent families protecting AsiDNA and its related compounds, alone or in combination.

Key Points: 
  • It completes the already robust set of patent families protecting AsiDNA and its related compounds, alone or in combination.
  • The granted patent is based on the fact that AsiDNA is able, through its original mechanism of action, to block all DNA repair pathways, including the homologous recombination pathway.
  • Now, another complementary application of AsiDNA appears, in combination with PARP inhibitors in HR-proficient patients with little or no sensitivity to PARPi alone.
  • AsiDNA has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors.

Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties

Retrieved on: 
Thursday, June 25, 2020
Branches of biology, Cell biology, DNA, Biology, PARP1, cGAS–STING cytosolic DNA sensing pathway, Biomarker, Treatment of cancer, PARP inhibitor

OX401 is a potent PARP1 agonist and represents a new generation of molecules showing strong anti-tumor activity associated with high immunological activity.

Key Points: 
  • OX401 is a potent PARP1 agonist and represents a new generation of molecules showing strong anti-tumor activity associated with high immunological activity.
  • OX401 exhibits potent antitumor activity, demonstrated in an animal model of breast cancer, related to PARP hyperactivation and diversion of its DNA repair function in specific tumor cells.
  • In addition, this activity on PARP induces a strong engagement of the cGAS-STING pathway2, as shown by the increase in key biomarkers of the tumor immune response.
  • Finally, like AsiDNA, OX401 has no activity on healthy cells, which should provide a favorable safety profile in the clinic.